Nektar Therapeutics (NKTR, Financial) experienced a significant stock price drop of 5.02%, trading at $0.666 per share with a trading volume of 1.89413 million shares. The stock's turnover rate was 1.03%, and its fluctuation amplitude reached 7.52%. Recent financial reports indicate that the company generated $24.12 million in revenue, with a net loss of $37.06 million, resulting in an earnings per share of -$0.18 and a gross profit of $19.69 million. The price-to-earnings ratio stands at -0.80.
In terms of analyst ratings, out of nine institutions covering the stock, 44% recommend buying, 44% suggest holding, and 12% advise selling. The broader biotech sector saw a decline of 0.71%. Within this sector, stocks like Conduit Pharmaceuticals Inc. and Surrozen Inc. showed significant gains, while others such as Conduit Pharmaceuticals Inc. and Tonix Pharmaceuticals Holding Corp. were active with high turnover rates of 8377.56% and 180.65%, respectively.
Nektar Therapeutics is a pharmaceutical company focused on developing therapies that selectively modulate the immune system to treat autoimmune diseases and cancer. Their pipeline includes clinical and preclinical stage immunomodulators targeting autoimmune diseases and cancer therapies.
